7:45 am Light Breakfast & Check-In
8:55 am Chair’s Opening Remarks
Breaking Barriers: Advancing TPD by Unveiling Novel Applications of Heterobifunctional Degraders in the Chromatin System & Beyond
9:00 am Rational Design of a Novel DCAF-16-Recruiting BRD9 Targeted Glue®
9:30 am Targeting ‘Undruggable’ Targets: Pioneering Novel Applications of Heterobifunctional Degrade
10:00 am Morning Break & Speed Networking
Discovery Track
Developing Next-Gen Platforms to Create Targeted Degraders with Enhanced Therapeutic Effects
Synopsis
Chair: Iacovos Michaelides, Associate Principal Scientist, AstraZeneca
11:00 am Expanding the Therapeutic Frontier: Targeted Protein Degradation in the Chromatin Regulatory System
11:30 am Applying Innovative Structural Biology Solutions to Resolve Binary & Ternary Complexes in TPD
11:40 am From Sequence to Glue: A Multi-Dimension Journey in the Embedding Space
Pre-Clinical & Translation Track
Leveraging Novel MoAs to Unlock New Disease Targets & Realise the Full Therapeutic Potential of Degraders
Synopsis
Chair: William McEwan, Sir Henry Dale Fellow, UK Dementia Research Institute, University of Cambridge
11:00 am Bridging Pharmacokinetics & Pharmacodynamics to Enhance the Pre-Clinical Efficacy of Degrader-Loaded ADCs Targeting SMARCA &CDK9 for Drug Development Optimisation
11:30 am Developing Optimised Folding Interfering Degraders Targeting Cyclin D1
12:15 pm Lunch Break & Networking
Accelerating Molecular Glue Discovery & Development to Unleash the Next- Generation of Induced Proximity Therapeutics
Synopsis
Chair: Iacovos Michaelides, Associate Principal Scientist, AstraZeneca
1:15 pm Multimodal Screening Strategy for Discovery of Novel Cereblon-Directing Molecular Glue Degraders & Neosubstrates
1:45 pm Unveiling Basal Protein-Protein Interactions to Drive Molecular Glue Discovery Across 200 Therapeutic Targets
2:15 pm Revolutionizing Molecular Glue Discovery Through High-Throughput Neomorphic Remodelling of Effector Proteins
Optimising Drug Development Through Case Studies on Molecular Design & Predictive PK-PD Studies to Ensure Successful Translation into the Clinic
Synopsis
Chair: Luc Brunsveld, Professor of Chemical Biology, Eindhoven University of Technology & Co-Founder, Ambagon Therapeutics
1:15 pm Optimising Pre-Clinical PROTAC Development: Predicting Bioavailability, Enhancing ADME Assays, & Overcoming DMPK Challenges for Clinical Translation
1:45 pm Targeting KRAS Mutations Beyond G12C: Advancing ACBI3 for Comprehensive KRAS Degradation and Tumour Regression
2:15 pm Pioneering a Differentiated Approach to Targeted Protein Degradation Using the Ubiquitin Conjugating Enzyme (E2) Family
2:45 pm Afternoon Networking Break & Poster Session
Harnessing Innovative Approaches for the Discovery of Effectors Beyond Cereblon & VHL to Develop Safer & Selective Degraders
Synopsis
Chair: Andreas Mantoulidis, Head of Medicinal Chemistry Lab, Boehringer Ingelheim